The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: -8.00 (-2.63%)
Spread: 4.00 (1.356%)
Open: 292.00
High: 298.00
Low: 292.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks down as aggressive US Fed rate hike looms

Tue, 03rd May 2022 12:14

(Alliance News) - Stock prices in London were lower at midday on Tuesday following the long bank holiday weekend in the UK, as markets globally prepare for a sharp US interest rate hike and similar moves by other central banks as they struggle to control inflation.

All eyes are on the conclusion on Wednesday of the Federal Reserve's two-day policy meeting, where it is expected to lift borrowing costs by half a percentage point. It would be the first time since 2000 that the US central bank has raised rates by 50 basis points at one meeting.

Earlier Tuesday, Australia joined the tightened cycle started by central banks elsewhere. The Sydney-based central bank raised the main lending rate by 25 basis points to 0.35%, the first increase since November 2010.

The FTSE 100 index was down 32.64 points, or 0.4%, at 7,511.91. The mid-cap FTSE 250 index was down 12.02 points, or 0.1%, at 20,696.69. The AIM All-Share index was down 2.31 points, or 0.1%, at 1,019.95.

The Cboe UK 100 index was down 0.7% at 745.25. The Cboe 250 was down 0.5% at 18,172.69. The Cboe Small Companies climbed 0.1% to 15,174.74.

In mainland Europe, the CAC 40 in Paris was up 0.2% and the DAX 40 in Frankfurt was up 0.4%.

"Markets are particularly worried about lockdown in China and how fast US interest rates might go up. We'll get clarity on the latter tomorrow when the Federal Reserve gives its latest policy decision, with markets expecting half a percentage point increase in the Fed Funds rate. Central banks typically raise rates by a quarter percentage point, but the Fed is under pressure to be more aggressive to combat rising inflation," said AJ Bell's Russ Mould.

The Bank of England will announce its own rate decision on Thursday.

"Can the BoE surprise with a 50bps hike at some point this year? The short answer: it's a long shot," commented Sanjay Raja, senior economist at Deutsche Bank. "While a bigger move may be on the table in the coming meetings, we see...reasons why a 50bps move remains unlikely in the UK, despite other central banks upping the ante for bigger moves."

Raja noted that the UK central bank moved early, so it doesn't need to catch-up with global peers. As well, more so than other advanced economies, the UK is at risk of falling into recession.

In the FTSE 100, M&G was up 3.0% at midday on Tuesday, after HSBC raised the investment manager to 'buy' from 'hold'.

In addition, St James's Place was up 1.9% after HSBC also upgraded the wealth manager to 'buy' from 'hold'.

BP was up 2.0%. The oil major swung to a first-quarter loss due to its decision to exit from its shareholding in Rosneft in response to Moscow's invasion of Ukraine; however on an underlying basis, the oil major reported a big jump in profit.

For the three months that ended March 31, BP swung to an attributable loss of USD20.38 billion from a USD4.67 billion profit in the first quarter last year. BP said the reported result included pretax adjusted items of USD30.8 billion.

By its preferred metric, BP swung to a replacement cost loss of USD23.04 billion from a replacement cost profit of USD3.33 billion the year before.

The London-based firm attributed the loss to its decision to exit its near-20% shareholding in state-owned Russian oil firm Rosneft. BP said that, in the first quarter, the total post-tax charge for this was USD25.5 billion.

On an underlying replacement cost basis, BP reported a profit of USD6.25 billion, up 54% from USD4.07 billion in the fourth quarter of last year and more than doubled from USD2.63 billion a year ago.

BP raised its first-quarter dividend by 4.0% to 5.46 cents from 5.25 cents the year before. Further, during the first quarter BP generated surplus cash flow of USD4.1 billion and said it intends to execute a USD2.5 billion share buyback prior to announcing its second quarter results.

Rival oil producer Shell, which posts its own first-quarter numbers on Thursday, was down 1.0%.

BP's results come as calls from the opposition Labour Party for a windfall tax on UK oil majors grow louder, as the country grapples with a cost-of-living crisis.

Last week, UK Chancellor of the Exchequer Rishi Sunak appeared to distance himself from such a tax but did not entirely rule it out.

The chancellor called on companies making generating large profit to invest the cash back into the UK instead.

"It sounds appealing. 'Great, we're taxing bad energy companies more, that will solve all our problems'," he said in an interview with Mumsnet. "The reason we haven't gone down that road is, really simply…we need to invest more. That's why we haven't gone for some extra tax. Because what I don't want to do is discourage investment in our own energy supplies."

The view was echoed by UK Prime Minister Boris Johnson who said on Tuesday that a windfall tax on big energy firms would deter investment and make it harder to meet the country's net-zero environmental goals.

At the other end of the large-caps, Segro was the worst performer, down 7.4%. Kepler Cheuvreux downgraded the warehouse property investor to 'hold' from 'reduce'.

In the FTSE 250, Auction Technology Group was the best performer, up 7.0%, after JPMorgan raised the online auction operator to 'overweight' from 'neutral'.

Energean was up 4.5%. Subsidiary Energean Israel signed a gas sales agreement with the East Hagit Power Plant Ltd Partnership.

Under the agreement, Energean will supply gas to East Hagit for a term of 15 years, with a total contract quantity of up to 12 billion cubic feet. Energean said the agreement has the potential to generate revenue of up to USD2 billion over the offtake period.

On AIM, Hutchmed (China) was down 15%, after the drugmaker said the US Food & Drug Administration has rejected its surufatinib for treatment of pancreatic neuroendocrine tumours.

In a complete response letter, the FDA said the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time".

The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively.

The dollar was higher across the board as the US Federal Reserve's two-day policy meeting gets underway. The pound was quoted at USD1.2512 at midday on Tuesday, down from USD1.2568 at the London equities close Friday.

The euro was priced at USD1.0517, down from USD1.0547. Against the Japanese yen, the dollar was trading at JPY130.11, up from JPY129.68.

On the economic front, UK manufacturing sector activity edged higher last month on increased intakes of new business against a backdrop of rising price inflationary pressures, S&P Global said.

The UK S&P Global-CIPS manufacturing purchasing managers' index was 55.8 points in April, up slightly from the preliminary estimate of 55.3 and the score of 55.2 registered in March.

S&P said the start of the second quarter saw a mild growth acceleration in the UK manufacturing sector. The rate of expansion in output improved from March's five-month low, leading to a further solid increase in staffing levels.

Brent oil was quoted at USD106.51 a barrel on Tuesday at midday, down sharply from USD110.30 at the London equities close on Friday. Gold stood at USD1,858.33 an ounce, down from USD1,906.75.

New York was pointed to a slightly lower open ahead of earnings reports from semiconductor maker Advanced Micro Devices, drugmaker Pfizer, and coffee-house chain Starbucks.

The Dow Jones Industrial Average was called down 0.2%, the S&P 500 down 0.1%, and the Nasdaq Composite down 0.3%, based on futures trading. The stock indices had closed up 0.3%, 0.6% and 1.6% respectively on Monday.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
8 Aug 2022 09:17

Hutchmed regulatory submission underway as fruquintinib trial succeeds

(Alliance News) - Hutchmed Ltd on Monday announced phase 3 of its fruquintinib FRESCO-2 study met its primary endpoint.

Read more
1 Aug 2022 15:16

TRADING UPDATES: Belvoir, Ingenta revenue up; Symphony revenue down

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
25 Jul 2022 15:59

UK earnings, trading statements calendar - next 7 days

Tuesday 26 July 
Aberforth Smaller Companies Trust PLCHalf Year Results
Ascential PLCHalf Year Results
Bytes Technology Group PLCTrading Statement
Capital & Counties Properties PLCHalf Year Results
Cohort PLCFull Year Results
Compass Group PLCTrading Statement
Dotdigital Group PLCTrading Statement
Drax Group PLCHalf Year Results
easyJet PLCTrading Statement
Ergomed PLCTrading Statement
Franchise Brands PLCHalf Year Results
Games Workshop Group PLCFull Year Results
Gore Street Energy Storage Fund PLCFull Year Results
Greencore Group PLCQ3 Results
John Menzies PLCTrading Statement
Medica Group PLCTrading Statement
Mitie Group PLCTrading Statement
NewRiver REIT PLCTrading Statement
Playtech PLCTrading Statement
Reach PLCHalf Year Results
Ricardo PLCTrading Statement
Sabre Insurance Group PLCHalf Year Results
SME Credit Realisation Fund LtdFull Year Results
Trifast PLCFull Year Results
Tyman PLCHalf Year Results
Unilever PLCHalf Year Results
Vivo Energy PLCHalf Year Results
Wickes Group PLCTrading Statement
Wednesday 27 July 
Aptitude Software Group PLCHalf Year Results
BlackRock Energy & Resources Income Trust PLCHalf Year Results
Breedon Group PLCHalf Year Results
British American Tobacco PLCHalf Year Results
FirstGroup PLCTrading Statement
Fresnillo PLCQ2 Production Results
GSK PLCHalf Year Results
Hargreaves Services PLCFull Year Results
Hiscox LtdTrading Statement
Ibstock PLCHalf Year Results
International Personal Finance PLCHalf Year Results
Lancashire Holdings LtdHalf Year Results
Lloyds Banking Group PLCHalf Year Results
Marston's PLCTrading Statement
Motorpoint Group PLCTrading Statement
musicMagpie PLCHalf Year Results
Nichols PLCHalf Year Results
Primary Health Properties PLCHalf Year Results
Quartix Technologies PLCHalf Year Results
Reckitt Benckiser Group PLCHalf Year Results
Rio Tinto PLCHalf Year Results
Smart Metering Systems PLCHalf Year Results
Smurfit Kappa Group PLCHalf Year Results
Ted Baker PLCTrading Statement
Unite Group PLCHalf Year Results
Wizz Air Holdings PLCQ1 Results
Yourgene Health PLCFull Year Results
Thursday 28 July 
Airtel Africa PLCTrading Statement
Anglo American PLCHalf Year Results
Aveva Group PLCTrading Statement
BAE Systems PLCHalf Year Results
Barclays PLCHalf Year Results
Bodycote PLCHalf Year Results
BT Group PLCQ1 Results
Centrica PLCHalf Year Results
CVS Group PLCTrading Statement
De La Rue PLCTrading Statement
Diageo PLCFull Year Results
discoverIE Group PLCTrading Statement
Dr Martens PLCTrading Statement
Elementis PLCHalf Year Results
FDM Group PLCHalf Year Results
Forterra PLCHalf Year Results
Foxtons Group PLCHalf Year Results
GB Group PLCTrading Statement
Greencoat UK Wind PLCHalf Year Results
Hammerson PLCHalf Year Results
Headlam Group PLCTrading Statement
Inchcape PLCHalf Year Results
Indivior PLCHalf Year Results
Informa PLCHalf Year Results
ITV PLCHalf Year Results
Jupiter Fund Management PLCHalf Year Results
Logistics Development Group PLCTrading Statement
Metro Bank PLCHalf Year Results
Mitchells & Butlers PLCTrading Statement
Mortgage Advice Bureau (Holdings) PLCTrading Statement
Mothercare PLCFull Year Results
MySale Group PLC Trading Statement
National Express Group PLCHalf Year Results
Quixant PLCTrading Statement
Rathbones Group PLCHalf Year Results
Relx PLCHalf Year Results
Rentokil Initial PLCHalf Year Results
Restore PLCHalf Year Results
Robert Walters PLCHalf Year Results
Schroders PLCHalf Year Results
Segro PLCHalf Year Results
Shell PLCHalf Year Results
Smith & Nephew PLCHalf Year Results
St James's Place PLCHalf Year Results
Vesuvius PLCHalf Year Results
Volex PLCHalf Year Results
Weir Group PLCHalf Year Results
Friday 29 July 
Allianz Technology Trust PLCHalf Year Results
Aston Martin Lagonda Global Holdings PLCHalf Year Results
AstraZeneca PLCHalf Year Results
Babcock International Group PLCFull Year Results
CMC Markets PLCTrading Statement
Croda International PLCHalf Year Results
Glencore PLCTrading Statement
IMI PLCHalf Year Results
Impellam Group PLCHalf Year Results
Industrials REIT LtdTrading Statement
International Consolidated Airlines Group SAHalf Year Results
Intertek Group PLCHalf Year Results
Law Debenture Corp PLCHalf Year Results
Morgan Advanced Materials PLCHalf Year Results
NatWest Group PLCHalf Year Results
Premier Miton Global Renewables Trust PLCHalf Year Results
Rightmove PLCHalf Year Results
Shearwater Group PLCFull Year Results
Standard Chartered PLCHalf Year Results
Walker Crips Group PLCFull Year Results
YouGov PLCTrading Statement
Monday 1 August 
Ascential PLCHalf Year Results
Cranswick PLCQ1 Results
Dialight PLCHalf Year Results
GlobalData PLCHalf Year Results
HSBC Holdings PLCHalf Year Results
Hutchmed (China) LtdHalf Year Results
NAHL Group PLCTrading Statement
Pearson PLCHalf Year Results
Spectris PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
15 Jul 2022 13:20

IN BRIEF: Hutchmed starts phase I trial of HMPL-A83

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins phase I trial of HMPL-A83 for patients with advanced malignant neoplasms, in China. HMPL-A83 is an investigational novel IgG4-type humanized anti-CD47 monoclonal antibody. Malignant neoplasms are cancerous tumours. It has "significant" potential to be used as a combination therapy with Hutchmed's existing portfolio, the firm says.

Read more
13 Jul 2022 09:35

IN BRIEF: Hutchmed presents solid results from lung cancer study

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Presents positive results from the Savannah phase two trial of Hutchmed and AstraZeneca PLC's savolitinib in combination with Astra's osimertinib in epidermal growth factor receptor-mutated non-small cell lung cancer patients.

Read more
6 Jul 2022 10:37

AIM WINNERS & LOSERS: Hutchmed down amid China Covid woes; Parkmead up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
6 Jul 2022 09:25

Hutchmed phase I trial for IMG-007 doses first patient

(Alliance News) - Hutchmed China Ltd on Wednesday announced the first patient has been dosed for its phase I trial for IMG-007.

Read more
1 Jun 2022 10:07

IN BRIEF: Hutchmed China wins cancer drug Tazverik approval in Hainan

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Receives approval for Tazverik from the Health Commission & Medical Products Administration of the Hainan province in China. The approval is for use in the Hainan pilot zone under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma and follicular lymphoma.

Read more
3 May 2022 11:29

AIM WINNERS & LOSERS: Hutchmed sinks on US FDA drug rejection

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
3 May 2022 11:25

IN BRIEF: US FDA says Hutchmed's pancreatic drug needs more testing

Hutchmed (China) Ltd - Hong Kong-based biopharmaceuticals - The US Food & Drug Administration has rejected Hutchmed's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA says the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively. Chief Executive Officer & Chief Scientific Officer Weiguo Su comments: "Although this decision from the FDA is disappointing, we remain confident about the clinical value of surufatinib for NET patients and committed to making surufatinib available to patients globally. We look forward to working with the agency to evaluate its feedback."

Read more
3 May 2022 08:57

LONDON MARKET OPEN: BP rises despite taking hit from Rosneft exit

(Alliance News) - Stock prices in London opened lower on Tuesday following the long bank holiday weekend, with BP shares rising as the oil major planned to return cash to shareholders amid calls by some UK politicians for a windfall profit tax on energy companies.

Read more
3 May 2022 07:53

LONDON MARKET PRE-OPEN: BP swings to quarterly loss after Rosneft exit

(Alliance News) - Stock prices in London are seen opening lower on Tuesday, after the long bank holiday weekend in the UK, as concerns rise over aggressive monetary policy tightening by the US Federal Reserve.

Read more
25 Apr 2022 10:45

AIM WINNERS & LOSERS: musicMagpie sells on new platform; Hutchmed down

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
20 Apr 2022 16:05

UK shareholder meetings calendar - next 7 days

Thursday 21 April 
Alliance Trust PLCAGM
Ibstock PLCAGM
Journeo PLCAGM
Relx PLCAGM
STV Group PLCAGM
Ruffer Investment Co LtdEGM re share issue
Friday 22 April 
Bellevue Healthcare Trust PLCAGM
Faron Pharmaceuticals LtdAGM
Murray International Trust PLCAGM
Monday 25 April 
Belluscura PLCAGM
Capital Gearing Trust PLCGM re non pre-emptive share issue
Cloudbreak Discovery PLCGM re Crescita equity drawdown agreement
Hikma Pharmaceuticals PLCAGM
JPMorgan US Smaller Cos Investment Trust PLCAGM
Polymetal International PLCAGM
Symphony International Holdings LtdAGM
Tuesday 26 April 
Aquis Exchange PLCAGM
Elementis PLCAGM
GlobalData PLCAGM
Oriole Resources PLCAGM
RPS Group PLCAGM
SigmaRoc PLCAGM
Taylor Wimpey PLCAGM
Tissue Regenix Group PLCAGM
Wednesday 27 April 
Drax Group PLCAGM
EP Global Opportunities Trust PLCAGM
Global Invacom Group LtdAGM
Hutchmed (China) LtdAGM
London Stock Exchange Group PLCAGM
McKay Securities PLCGM re Workspace offer
Nichols PLCAGM
Persimmon PLCAGM
Primary Health Properties PLCAGM
VH Global Sustainable Energy Opportunities PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.